Recombinant von Willebrand factor: Potential therapeutic use

Journal of Thrombosis and Thrombolysis

Volumn 8, Issue 3, 1999, Pages 197-205

  Fischer, Bernhard E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Bleeding; Collagen binding; Platelet aggregation; Recombinant; von Willebrand factor

Indexed keywords

COLLAGEN; VON WILLEBRAND FACTOR;

ARTICLE; DOG; DRUG SYNTHESIS; HUMAN; MAMMAL CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN PROCESSING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; VON WILLEBRAND DISEASE;

BLOOD PLATELETS; GLYCOSYLATION; HUMANS; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; VON WILLEBRAND FACTOR;

EID: 0032705572     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008906103637     Document Type: Article

References (76)

1. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost 1994;71:520-525.
2. Ginsburg D, Sadler JE. Von Willebrand disease: A database of point mutations, insertions, and deletions. Thromb Haemost 1993;69:177.
3. Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost 1992;67:594-599.
4. Ruggeri ZM, Zimmerman TS. The complex multimeric composition of factor VIII/von Willebrand factor. Blood 1981;57:1140-1143.
5. Ruggeri ZM, Ware J. Von Willebrand factor. FASEB J 1993;7:308-316.
6. Mannucci PM, Abildgaard CF, Gralnick HR, et al. Multicenter comparison of von Willebrand factor multimer sizing techniques. Thromb Haemost 1985;54:873-877.
7. Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost 1993;19:37-47.
8. Menache, D, Aronson, DL. New treatment of von Willebrand disease: Plasma derived von Willebrand factor concentrates. Thromb Haemost 1997;78:566-570.
9. Mannucci, PM, Lattuada A, Ruggeri ZM. Proteolysis of von Willebrand factor in therapeutic plasma concentrates. Blood 1994;83:3018-3027.
10. Fareed J, Hoppensteadt D, Iyer L, Koza M, Walenga J, Bermes E. Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. In: Nutrition and Biotechnology in Heart Disease and Cancer. New York: Plenum Press, 1995:99-110.
11. Storch H. Recombinant plasma proteins for therapeutic use-status and developmental trends. Beitr Infusionsther 1993;31:31-37.
12. Brettler DB. Recombinant coagulation factor products. Haemophilia 1995;1:155-168.
13. Lynch DC. The fine structure of von Willebrand factor multimers and type IIa von Willebrands disease. Ann N Y Acad Sci 1993;138:138-152.
14. Pannekoek H, Voorberg J. Molecular cloning, expression and assembly of multimeric von Willebrand factor. Bailliere's Clin Haematol 1989;2:879-896.
15. Carew JA, Browning PJ, Lynch DC. Sulfatation of von Willebrand factor. Blood 1990;76:2530-2539.
16. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor. Proc Natl Acad Sci USA 1990;87: 6306-6310.
17. Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constotuent subunit. J Clin Invest 1991; 88:774-782.
18. Furlan M, Robles R, Affolter D, Meyer D, Baillod P, Lämmle B. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 1993;90:7503-7507.
19. Furlan M, Robles R, Lämmle B. Purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-4234.
20. Bonthron DT, Handin RI, Kaufman RJ, et al. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature 1986;324:270-273.
21. Sixma JJ, Schiphorst ME, Verwij CL, Pannekoek H. Effects of deletion of the A1 domain of von Willebrand factor on first binding to heparin, collagen and platelets in the presence of ristocetin. Eur J Biochem 1991;196:369-375.
22. Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen. J Biol Chem 1995;270:10822-10827.
23. Ribba AS, Voorberg J, Meyer D, Pannekoek H, Pieto G. Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease. J Biol Chem 1992;267:23209-2315.
24. Wise, RJ, Pittman DD, Handin RI, Kaufman RJ, Orkin SH. The propeptide of von Willebrand factor independently mediates the assembly of von Willebrand multimers. Cell 1988;52:229-236.
25. Verweij CL, Hart M, Pannekoek H. Expression of variant von Willebrand factor (vWf) cDNA in heterologous cells: Requirement of the pro-polypeptide in vWf multimer formation. EMBO J 1987;6:2885-2890.
26. Meulien P, Nishino M, Mazurier C, et al. Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector. Thromb Haemost 1992;67:54-160.
27. Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc Natl Acad Sci USA 1992;89:3531-3535.
28. Kaufman RJ, Wasley LC, Davies MV, Wise RJ, Israel DI, Dorner AJ. Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in Chinese hamster ovary cells. Mol Cell Biol 1989;9:1233-1242.
29. Voorberg J, Frontijn R, Calafat J, Janssen H, van Mourik JA, Pannekoek H. Biogenesis of von Willebrand factor-containing organelles in heterologous transfected CV-1 cells. EMBO J 1993;12:749-758.
30. Randi AM, Jorieux S, Tuley EA, Mazurier C, Sadler JE. Recombinant von Willebrand factor Arg578-> Gln. J Biol Chem 1992;267:21187-21192.
31. Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman R. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 1991;266:21948-21955.
32. Matsushita T, Sadler JE. Identification of amino acids residues essential for von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1995;270:13406-13414.
33. Lankhof H, Wu YP, Vink T, Schiphorst ME, Zerwes HG, de Groot G, Sixma JJ. Role of the glycoprotein Ib-binding A1 repeat and the RGD sequence in platelet adhesion to human recombinant von Willebrand factor. Blood 1995;86: 1035-1042.
34. Carew JA, Quinn SM, Stuart JH, Lynch DC. O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein Ib. J Clin Invest 1992;90:2258-2267.
35. Rabinowitz I, Randi AM, Shindler KS, Tuley EA, Rustagi PK, Sadler JE. Type IIB mutation His-505-Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J Biol Chem 1993;268: 20497-20501.
36. Jorieux S, Tuley EA, Gaucher C, Mazurier C, Sadler J.E. The mutation Arg (53);sg Trp causes von Willebrand desease normandy by abolishing binding to factor VIII. Studies with recombinant von Willebrand factor. Blood 1992; 79:563-567.
37. Azuma H, Sugimoto M, Ruggeri ZM, Ware J. A role for von Willebrand factor proline residues 702-704 in ristocetin-mediated binding to platelet glycoprotein Ib. Thromb Haemost 1993;69:192-196.
38. Azuma H, Dent JA, Sugimoto M, Ruggeri ZM, Ware J. Independent assembly and secretion of a dimeric adhesive domain of von Willebrand factor containing the glycoprotein Ib-binding site. J Biol Chem 1991;266:12342-12347.
39. Hilbert L, Gaucher C, de Romeuf C, Horellou MH, Vink T, Mazurier C. Leu697 → Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 1994;83:1542-1550.
40. Hayashi T, Ware J, Niiya K, Sakuragawa N. Isolated recombinant domain of von Willebrand factor displaying increased sensitivity to ristocetin. Am J Hematol 1996;52:248-253.
41. Journet AM, Saffaripour S, Wagner DD. Requirement for both D domains of the propolypeptide in von Willebrand factor multimerization and storage. Throm Haemost 1993;70:1053-1057.
42. Pannekoek H, Voorberg J. Molecular cloning, expression and assembly of multimeric von Willebrand factor. Bailliere's Clin Haematol 1989;2:879-896.
43. Azuma H, Hayashi T, Dent JA, Ruggeri ZM, Ware J. Disulfide bond requirement for assembly of the platelet glycoprotein Ib-binding domain of von Willebrand factor. J Biol Chem 1993;268:2821-2827.
44. Prior C, Chu V, Holt J, et al. Production and functional characterization of a recombinant fragment of von Willebrand factor (vWF): An antagonist to platelet receptor GP Ib. Bio/Technol 1992;10:66-73.
45. Prior CP, Chu V, Cambou B, et al. Optimization of a recombinant von Willebrand factor fragment as an antagonist to the platelet receptor GP Ib receptor. Bio/Technol 1993;11: 709-713.
46. Schneppenheim R, Brassard J, Krey S, et al. Defective dimerization of von Willebrand factor subunits due to a Cys→Arg mutation in type IID von Willebrand disease. Proc Natl Acad Sci USA 1996;93:3581-5386.
47. Fischer B, Mitterer A, Dorner F. Structural analysis of recombinant von Willebrand factor: Identification of hetero- and homo-dimers. FEBS Lett 1994;351:345-348.
48. Fischer BE, Schlokat U, Mitterer A, et al. Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin. FEBS Lett 1995;375:259-262.
49. Schlokat U, Fischer B, Herlitschka S, et al. Production of highly homogeneous and structurally intact recombinant von Willebrand factor multimers by Furin mediated propeptide removal in vitro. Biotechnol Appl Biochem 1996;24: 257-267.
50. Schlokat U, Fischer B, Mitterer A, et al. Herstellung und Charakterisierung von rekombinantem von Willebrand Faktor zur therapeutischen Anwendung. Hämophilie-Symposium Hamburg 1995, Berlin : Springer Verlag, 1996: 147-158.
51. Fischer B, Schlokat U, Reiter M, Mundt W, Dorner F. Biochemical and functional characterization of recombinant von Willebrand factor. Cell Mol Life Sci 1997;53:943-950.
52. Fischer BE, Thomas K, Schlokat U, Dorner F. Triplet structure of human von Willebrand factor. Biochem J 1998;331: 483-488.
53. Fischer BE, Kramer G, Mitterer A, et al. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thromb Res 1996;84:55-66.
54. Fischer BE, Thomas KB, Dorner F. Collagen covalently immobilized onto plastic surfaces simplifies measurement of von Willebrand factor-collagen binding activity. Ann Hematol 1998;76:159-166.
55. Dong Z, Thoma RS, Crimmins DL, McCourt DW, Tuley EA, Sadler JE. Disulfide bonds required to assemble functional von Willebrand factor multimers. J Biol Chem 1994;269: 6753-6758.
56. Englender T, Lattuada A, Mannucci P, Sadler JE, Inbal A. Analysis of Arg834Gln and Val902Glu von Willebrand disease mutations. Blood 1996;87:2788-2794.
57. Lankhof H, Damas C, Schiphorst ME, et al. Von Willebrand factor without the A2 domain is resistant to proteolysis. Thromb Haemost 1997;77:1008-1013.
58. Schlokat U, Preininger A, Himmelspach M, Mohr G, Fischer B, Dorner F. High yield production of recombinant plasma factors: Use of recombinant endoprotease derivatives in vivo and in vitro. In: Animal Cell Technology, Boston Kluwer, 1998.
59. Steiner DF, Smeekens SP, Ohagi S, Chan SJ. The new enzymology of precursor processing endoproteases. J Biol Chem 1993;267:23435-23438.
60. Vey M, Schîer W, Berghöfer S, Klenk HD, Garten W. Maturation of the trans-Golgi network protease furin: Compartmentalization of propeptide removal, substrate cleavage, and COOH-terminal truncation. J Cell Biol 1994;127: 1829-1842.
61. Molloy SS, Thomas L, Van Slyke JK, Stenberg PE, Thomas G. Intracellular trafficking and activation of the furin proprotein convertase: Localization to the TGN and recycling from the cell surface. EMBO J 1994;13:18-33.
62. Leduc R, Molloy SS, Thorne BA, Thomas G. Activation of human furin precursor processing endoprotease occurs by an intramolecular autoproteolytic cleavage. J Biol Chem 1992;267:14304-14308.
63. Fischer B, Mitterer A, Dorner F. Comparison of N-glycan pattern of recombinant human coagulation factors expressed in Chinese hamster ovary (CHO) and African green monkey (Vero) cells. Coagulation factors II and IX. J Thromb Thrombolys 1996;3:57-62.
64. Meyer D, Girma JP. Von Willebrand factor: Structure and function. Thromb Haemost 1993;70:99-104.
65. Fleming TGM. Von Willebrand factor: Its function and its measurement in the laboratory. Br J Biomed Sci 1995;52: 50-57.
66. Furlan M. Von Willebrand factor: Molecular size and functional activity: Ann Hematol 1996;72:341-348.
67. Vlot AJ, Koppelman SJ, van den Berg MH, Bouma BN, Sixma JJ. The affinity and stoichiometry of binding of human factor VIII to von Willebrand factor. Blood 1995;85: 3150-3157.
68. Leyte A, Verbeet M, Brodniewicz-Proba T, van Mourik J, Mertens K. The interaction between human blood-coagulation factor VIII and von Willebrand factor: Characterization of a high-affinity binding site on factor VIII. Biochem J 1989;257:679-683.
69. Turecek PL, Siekmann J, Pichler L, et al. Rekombinanter von Willebrand-Faktor: Präklinik. Hämophilie-Symposium Hamburg 1995, Berlin: Springer Verlag, 1996:159-168.
70. Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997;90:3555-3567.
71. Drouet L, Roussi J, Bonneau M, et al. The effect of recombinant human von Willebrand factor in pigs with severe von Willebrand's disease. Blood 1995;81 (Suppl. 1):612.
72. Ruggeri ZM. Structure and function of von Willebrand factor: Relationship to von Willebrand's disease. Mayo Clin Proc 1991;66:847-861.
73. Berntrop E. Plasma product treatment in various types of von Willebrands's disease. Haemostasis 1994;24:289-297.
74. Aledort LM. Treatment of von Willebrand's disease. Mayo Clin Proc 1991;66:841-846.
75. Nichols W, Ginsburg D. Von Willebrand disease. Medicine [Baltimore] 1997;76:20.
76. Berntrop E. Plasma product treatment in various types of von Willebrand's disease. Haemostasis 1994;24:289-297.